Hospital General Universitario de Alicante -ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2023

  1. Is unicentric familial papillary thyroid microcarcinoma different from multicentric?

    Endocrine, Vol. 82, Núm. 3, pp. 613-621

2022

  1. Biological behavior of familial papillary thyroid microcarcinoma: Spanish multicenter study

    Langenbeck's Archives of Surgery, Vol. 407, Núm. 8, pp. 3631-3642

  2. Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors

    Diabetes Research and Clinical Practice, Vol. 184

2020

  1. One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1052-1061

2019

  1. Chronic Kidney Disease and Third-Generation P2Y 12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year

    Journal of Clinical Pharmacology, Vol. 59, Núm. 2, pp. 295-302

  2. Switching of Oral P2Y 12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis

    Clinical Drug Investigation, Vol. 39, Núm. 3, pp. 275-283

  3. Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome

    European Journal of Internal Medicine, Vol. 61, pp. 48-53

  4. Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease

    Minerva Medica, Vol. 110, Núm. 5, pp. 410-418

2018

  1. Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines

    PLoS ONE, Vol. 13, Núm. 11

  2. Disparities in the estimation of glomerular filtration rate according to cockcroft-gault, modification of diet in renal disease-4, and chronic kidney disease epidemiology collaboration equations and relation with outcomes in patients with acute coronary syndrome

    Journal of the American Heart Association, Vol. 7, Núm. 9

  3. Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes

    Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 23, Núm. 1, pp. 57-65

2017

  1. Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry

    European Journal of Cardiovascular Nursing, Vol. 16, Núm. 8, pp. 696-703

  2. Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome

    Oncotarget, Vol. 8, Núm. 46, pp. 80182-80191

2016

  1. Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy

    European Journal of Clinical Investigation, Vol. 46, Núm. 2, pp. 123-129

2015

  1. Effects of body mass index on the lipid profile and biomarkers of inflammation and a fibrinolytic and Prothrombotic state

    Journal of Atherosclerosis and Thrombosis, Vol. 22, Núm. 6, pp. 610-617

  2. Involvement of the -420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy

    Journal of Internal Medicine, Vol. 278, Núm. 1, pp. 50-58

2014

  1. Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy

    QJM, Vol. 107, Núm. 8, pp. 613-621

2013

  1. Identification and confirmation of haptoglobin as a potential serum biomarker in hypertrophic cardiomyopathy using proteomic approaches

    Annals of Medicine, Vol. 45, Núm. 4, pp. 341-347

2012

  1. High-sensitivity troponin T and Copeptin in Non-ST acute coronary syndromes: Implications for prognosis and role of hsTnT and copeptin in non-STEACS

    TheScientificWorldJournal, Vol. 2012

  2. Usefulness of β-trace protein and cystatin C for the prediction of mortality in non ST segment elevation acute coronary syndromes

    American Journal of Cardiology, Vol. 110, Núm. 9, pp. 1240-1248